Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 5, 2006, Pages 418-426

  Poria, Rahul B ^a   Norenberg, Jeffrey P ^b   Anderson, Tamara L ^b   Erion, Jack ^c   Wagner, Carston R ^d   Arterburn, Jeffrey B ^e   Larson, Richard S ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Biosynthemia Inc   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e NEW MEXICO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Butylamino NorBIRT; Leukocyte function associated antigen 1; Lutetium 177; Lymphoma; Radionuclide imaging

Indexed keywords

1 (4 AMINOBUTYL) 5 (4 BROMOBENZYL) 3 (3,5 DICHLOROPHENYL) 5 METHYLIMIDAZOLIDINE 2,4 DIONE; 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID BUTYLAMINO 1 (4 AMINOBUTYL) 5 (4 BROMOBENZYL) 3 (3,5 DICHLOROPHENYL) 5 METHYLIMIDAZOLIDINE 2,4 DIONE; 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''',TETRAACETIC ACID; BIRT 377; LUTETIUM 177; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BINDING; EQUILIBRIUM CONSTANT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA; LEUKOCYTE; LYMPHOMA; MOLECULAR STABILITY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; RADIOCHEMISTRY;

ANIMALS; BINDING, COMPETITIVE; HETEROCYCLIC COMPOUNDS, 1-RING; HL-60 CELLS; HUMANS; HYDANTOINS; IMIDAZOLIDINES; ISOTOPE LABELING; KINETICS; LEUKEMIA; LUTETIUM; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; LYMPHOMA; MICE; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES;

EID: 33750982424     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.418     Document Type: Article

References (14)

1. Larson RS, Davis T, Bologa C, et al. Dissociation of I domain and global conformational changes in LFA-1: Refinement of small molecule-1 domain structure-activity relationships. Biochemistry 2005;44:4322.
2. Inghirami G, Wieczorek R, Zhu BY, et al. Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia. Blood 1988;72:1431.
3. Horst E, Radaszkiewicz T, Hooftman-den Otter A, et al. Expression of the leucocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia 1991;5:848.
4. Bechter OE, Eisterer W, Dirnhofer S, et al. Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL). Leuk Res 1999;23:483.
5. Kelly TA, Jeanfavre DD, McNeil DW, et al. Cutting edge: A small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol 1999;163:5173.
6. Last-Barney K, Davidson W, Cardozo M, et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: Evidence for the allosteric inhibition of a protein-protein interaction. J Am Chem Soc 2001;123:5643.
7. 177Lu-DOTA-Tyr-3-octreotate in an animal model. J Nucl Med 2004;45:1542.
8. Johnston SC, Dustin ML, Hibbs ML, et al. On the species specificity of the interaction of LFA-1 with intercellular adhesion molecules. J Immunol 1990;145:1181.
9. Kaufmann Y, Tseng E, Springer TA. Cloning of the murine lymphocyte function-associated molecule-1 alpha-subunit and its expression in COS cells. J Immunol 1991;147:369.
10. Morion KA, Jarboe J, Burke EM. Gallium-67 imaging in lymphoma: Tricks of the trade. J Nucl Med Technol 2000;28:221.
11. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30(Suppl. 1):S117.
12. Panayi GS, Hainsworth JD, Looney RJ, et al. Panel discussion on B-cells and rituximab: Mechanistic aspects, efficacy, and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. Rheumatology (Oxford) 2005;44 (Suppl. 2):ii18.
13. Emmanouilides C. Radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol 2003;30:531.
14. Hainsworth JD, Burris HA, 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 2000;95:3052.